Immunocore plans to unveil TEBE-AM trial data by year-end 2026 while scaling KIMMTRAK to over 1,000 patients annually.
Immunocore Holdings (IMCR) outlined plans to release early TEBE-AM clinical data by the end of 2026, as the company focuses on expanding its oncology and infectious disease pipeline. The biotech aims to scale KIMMTRAK, its lead therapy, to treat more than 1,000 patients per year.
Management highlighted three strategic priorities during its Q2 2026 earnings call: maximizing KIMMTRAK’s value, advancing its melanoma portfolio, and broadening applications into other tumor types, infections, and autoimmune diseases. The company did not provide specific financial guidance but emphasized execution on these goals.
Shares of IMCR showed limited immediate reaction to the update, reflecting investor focus on upcoming clinical milestones rather than near-term financial performance.